What is the recommended follow‑up and management strategy for a patient with chronic kidney disease, including blood pressure control, diabetes management, dietary restrictions, anemia treatment, monitoring parameters, and timing of renal replacement therapy?

Comprehensive CKD Follow-Up and Management Strategy

All adults with CKD should receive foundational therapy with an SGLT2 inhibitor (starting at eGFR ≥20 ml/min/1.73m²), RAS inhibitor (ACEi or ARB) for those with albuminuria or hypertension, and a statin, combined with structured monitoring every 3-6 months for disease progression and cardiovascular risk. 1, 2

Blood Pressure Control

Target BP management using RAS inhibitors as first-line therapy:

• Initiate ACEi or ARB at the highest approved tolerated dose to achieve proven trial benefits 1
• Monitor BP, serum creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
• Continue therapy unless creatinine rises >30% within 4 weeks of starting or dose escalation 1
• Do NOT discontinue when eGFR falls below 30 ml/min/1.73m² - continue RAS inhibition even at advanced stages 1

Managing common complications:

• For hyperkalemia: implement potassium-lowering measures rather than stopping RASi 1
• For symptomatic hypotension or uncontrolled hyperkalemia despite treatment: consider dose reduction 1
• Only reduce/discontinue at eGFR <15 ml/min/1.73m² if needed to reduce uremic symptoms 1

Diabetes Management (Type 2 Diabetes)

Implement a three-drug foundation for T2D with CKD:

1. SGLT2 inhibitor (eGFR ≥20 ml/min/1.73m²) - strongest recommendation 1

   • Continue even if eGFR drops below 20 unless dialysis initiated 1
   • Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
   • The reversible eGFR dip at initiation does NOT require discontinuation 1

2. Metformin when eGFR ≥30 ml/min/1.73m² 2

3. GLP-1 receptor agonist if additional glycemic control needed or SGLT2i/metformin contraindicated 2

For patients with persistent albuminuria (>30 mg/g) despite maximum RASi:

• Add nonsteroidal MRA (finerenone) if eGFR >25 ml/min/1.73m², normal potassium, and high cardiovascular/progression risk 1, 2
• Can be combined with RASi + SGLT2i 1

SGLT2 Inhibitor Indications (All Adults with CKD)

Strong indications (1A recommendation):

• eGFR ≥20 ml/min/1.73m² with urine ACR ≥200 mg/g 1
• Heart failure at any albuminuria level 1

Moderate indication (2B recommendation):

• eGFR 20-45 ml/min/1.73m² with ACR <200 mg/g 1

Cardiovascular Risk Reduction

Universal statin therapy for all patients with diabetes and CKD 2

Antiplatelet therapy for those with established atherosclerotic cardiovascular disease 2

Dietary Restrictions

The 2024 KDIGO guideline emphasizes lifestyle modifications including dietary changes as the foundation, though specific restrictions should be tailored to CKD stage 2, 3:

• Sodium restriction for BP control
• Protein modification based on stage
• Phosphate management (particularly stages 4-5)
• Weight management 2

Anemia Treatment

Monitor hemoglobin and iron parameters regularly 4, 5

Iron management:

• Proactive IV iron use in hemodialysis patients 6
• Address iron deficiency even without anemia 4

Erythropoiesis-stimulating therapy:

• Prefer ESAs over HIF-prolyl hydroxylase inhibitors as first-line due to greater safety familiarity 6, 5
• HIF-PHIs are newer alternatives with emerging evidence 4, 5

Minimize red blood cell transfusions - reserve for specific indications 5

Monitoring Parameters and Frequency

Every 3-6 months, reassess: 2

• eGFR and albuminuria (urine ACR)
• Serum creatinine
• Electrolytes (potassium, bicarbonate)
• Hemoglobin and iron studies
• Lipid profile
• Blood pressure
• Glycemic control (if diabetic)

Within 2-4 weeks of RASi initiation/dose change: 1

• BP
• Serum creatinine
• Serum potassium

Consider serum cystatin C for GFR estimation in specific populations for drug dosing 7

Timing of Renal Replacement Therapy

Use the Kidney Failure Risk Equation to identify high-risk patients requiring nephrology referral 8

Refer to nephrology for:

• Advanced CKD (typically eGFR <30 ml/min/1.73m²)
• Rapidly progressive disease
• Complications requiring specialist management 3

Initiate KRT planning well before eGFR <15 ml/min/1.73m² to allow for:

• Vascular access creation (if hemodialysis planned)
• Transplant evaluation
• Patient education on modality options

Critical Pitfalls to Avoid

• Do NOT stop RASi when eGFR declines unless creatinine rises >30% acutely 1
• Do NOT discontinue SGLT2i for the expected initial eGFR dip 1
• Do NOT withhold RASi for mild hyperkalemia - treat the potassium instead 1
• Do NOT delay SGLT2i initiation - benefits extend beyond diabetes to all CKD with proteinuria/heart failure 1
• Do NOT forget nephrotoxin stewardship - educate on sick day medication management 7